• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제32권5호
• /
• pp.442-446
• /
• 2010

Purpose: The purpose of this study was to compare the clinical efficacy of popular bone graft materials mineralized allograft and deproteinized bovine bone mineral. Materials and Methods: One hundred seven implants of 78 patients, accompanied by sinus lift using the lateral window technique and simultaneous implantation, were sampled. In addition, some patients with severe systemic conditions were excluded. The initial bone heights of all patients ranged from 3-6 mm. All of the sample cases were treated at our hospital from January 2005 to January 2008. Techniques other than the lateral window technique were excluded, and only one graft material ($Tutoplast^{(R)}$ or Bio-$Oss^{(R)}$) was accepted for inclusion. $Tutoplast^{(R)}$ was used in 63 implants of 41 patients, whereas Bio-$Oss^{(R)}$) was chosen for the remaining 44 implants of 37 patients. The diameters of the particles used ranged from 0.25-1.0 mm, and the volume was 0.5-2 cc (mean, 1.5 cc). Results: The survival rate of the implant fixtures was 99.07% when the lateral window technique was used. Among all of the cases, cases in which $Tutoplast^{(R)}$ was used demonstrated a survival rate of 98.4%, whereas Bio-$Oss^{(R)}$) resulted in 100% survival. With respect to the alveolar bone height, no significant differences were detected between the two graft materials that failed. Conclusion: According to the result reported above, the two common materials for sinus augmentation do not have clinically significant difference. Rather, host factors, such as the height of residual bone, which could be disclosed during questioning patients' systemic conditions, might have greater effects on the prognosis.

• Journal of Chest Surgery
• /
• 제38권9호
• /
• pp.595-600
• /
• 2005

배경: 콜키신(Colchicine)은 면역 억제 작용을 갖고 있어 자가 면역 질환인 통풍(Gout)등의 질환의 치료제로 이용되어 왔다. 본 연구는 콜키신을 동종이형의 심장이식된 백서에 투여하여 면역억제효과를 확인하고자 하였다. 대상 및 방법: 백서에서의 동종이형 심장이식 거부 반응에 대하여 면역억제제를 투여하지 않는 대조군(Control group)(n=6)과 사이클로스포린(Cyclosporin A) 투여군(n=20), 콜키신 변형물질 투여군(n=20)을 비교함으로써 콜키신의 면역 억제 효과를 비교 검토하였다. 결과: 면역억제제를 투여하지 않은 대조군(n=6)에서는 모두 3주 이내에 거부반응을 보였고, 사이클로스포린(Cyclosporin A) 투여군(n=20)에서는 감염으로 추정되는 한 마리가 술 후 18일째 죽었고, 나머지 19마리는 100일 이상 생존하였다. 또한 콜키신 변형물질 투여군(n=20)에서도 술 후 9일 째에 마취 문제로 인한 호흡부전으로 한 마리가 사망한 외에 나머지는 100일 이상 생존하였다. 결론:본 실험에서는 백서에서의 동종이형 심장 이식 후 현재 면역억제제로 널리 사용되고 있는 Cyclosporin A 투여군과 콜키신 변형물질 투여군을 비교하여 본 바 콜키신 변형 물질 투여군에서도 Cyclosporin A 투여군과 마찬가지로 장기 생존의 결과를 얻을 수 있어 면역 억제 효과가 있음을 알 수 있었다.

• Archives of Reconstructive Microsurgery
• /
• 제21권1호
• /
• pp.34-40
• /
• 2012

Prevention of acute rejection in composite tissue allotransplantation without continuous immunosuppression lacks reports in worldwide literature. Recently dendritic cells (DC) gained considerble attention as antigen presenting cells that are also capable of immunologic tolerance induction. This study assesses the effect of alloantigen-pulsed dendritic cells in induction of survival in a rat hindlimb allograft. We performed hindlimb allotransplantation between donor Sprague-Dawley and recipient Fischer344 rats. Recipient derived dendritic cells were harvested from rat whole blood and cultured with anti-inflammatory cytokine IL-10. Then donor-specific alloantigen pulsed dendritic cells were reinjected into subcutaneous tissue before limb transplantation. Groups: I) untreated (n=6), II) DC injected (n=6), III) Immunosuppressant (FK-506, 2 mg/Kg) injected (n=6), IV) DC and immunouppressant injected (n=6). Graft appearance challenges were assessed postoperatively. Observation of graft appearance, H-E staning, immunohistochemical (IHC) study, and confocal immunofluoreiscece were performed postoperatively. Donor antigen pulsed host dendritic cell combined with short-term immunosuppression showed minimal mononuclear cell infiltration, regulator T cell presence, and could prolong limb allograft survival.

• 대한정형외과학회지
• /
• 제56권1호
• /
• pp.42-50
• /
• 2021

목적: 종양인공관절 주위 골절은 안정된 고정의 어려움과 골유합 후에도 골질 약화로 해리 및 재골절 위험이 많다. 피질골 지주 중첩 동종골 이식술을 종양인공관절 주위 골절에 적용하면 내고정도 쉽고, 골유합 기간도 단축되며, 합병증도 줄일 수 있을 것이라고 생각하였다. 본 연구는 종양인공관절 주위 골절 27예(30 골절)의 골절의 양상과 치료 후 재건 술식에 따른 생존율 및 합병증, 중첩 동종골 이식술 추가 여부에 따라 골유합 기간 및 기능적 결과가 차이가 있는지 분석하였다. 대상 및 방법: 골절 치료 시 판형 동종골 이식을 한 군 16예와 시행하지 않은 군 14예를 비교하였다. 분석항목은 종양인공관절 치환술부터 골절까지 기간, 골절의 양상, 골유합 기간 차이, 합병증, 및 기능적 결과를 기술하였다. 결과: 골절 양상은 unified classification system (UCS) B형이 21예(70.0%, 21/30)로 가장 많았으며 그 중 B1이 14예(46.7%, 14/30), B2가 1예(3.4%, 1/30), B3가 6예(20.0%, 6/30)였고 C형이 9예(30.0%, 9/30)였다. Kaplan-Meier 법에 의한 30 재건 부위의 5년, 10년 생존율은 각각 84.5%±4.18%, 42.2%±7.83%였다. 전체 30예의 골유합 기간은 평균 5.1개월(범위, 2.0-11.2개월)이었다. 동종골 이식군은 평균 3.5개월(범위, 2.0-6.26개월)로 고식적 고정군의 평균 7.2개월(범위, 4.0-11.2개월)보다 짧았다(p<0.0001). 최종 기능평가상 동종골 이식군은 평균 26.1점으로 고식적 고정군의 평균 20.9점보다 높았다(p<0.0001). 합병증은 4예로 모두 동종골을 사용하지 않은 군에서 있었다. 결론: 종양인공관절 주위 골절은 드물고 골유합도 비교적 잘 이루어지나 유합 후 합병증 최소화가 중요하다. 판형 중첩 동종골 이식술은 골유합 기간을 단축, 골질 증가, 해리위험성 감소 효과가 있으며 종양인공관절 주위 골절에 유용한 방법이다.

• Biomolecules & Therapeutics
• /
• 제13권2호
• /
• pp.65-77
• /
• 2005

Present article reviews about clinical pharmacology of mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF), as widely used component of immunosuppressive regimens in the organ transplantation field. MMF, used alone or concomitantly with cyclosporine or tacrolimus, has approved in reducing the incidence of acute rejection and has gained widespread use in solid organ such as kidney, heart and liver transplantation. The application of MPA and development of MMF has shown a considerable impact on immunosuppressive therapy for organ transplantation as a new immunosuppressive agent with different mechanism of action from other drugs after early 1990s. In particular aspect, use of MMF, a morpholinoethyl ester of MPA, represented a significant advance in the prevention of organ allograft rejection as well as allograft and patient survival. In considering MMF clinical data, it is important to note that there is a strong correlation between high MPA area under curve(AUC) values and a low probability of acute allograft rejection. Individual trials have shown that MMF is generally well tolerated and revealed that MMF decreased the relative risk of developing chronic allograft rejection compared with azathioprine. Recent clinical investigations suggested that improved effectiveness and tolerability will results from the incorporation of MPA therapeutic drug monitoring into routine clinical practice, providing effective MMF dose individualization in renal and heart transplant patients. Therefore, MMF has a selective immunosuppressive effect with minimal toxicity and has shown to be more effective that other agents as next step of immunosuppressive agents and regimens that deliver effective graft protection and immunosuppression along with a more favorable side effect.

• 한국임상수의학회지
• /
• 제18권4호
• /
• pp.358-362
• /
• 2001

Brain dead (BD) patients remain the largest source of solid organs for transplantation. BD has shown to decrease graft function and survival in rodent models. The aim of this study was to evaluate how brain death affects graft viability in the donor and kidney tolerance to cold preservation as assessed by survival in a canine transplantation. 13 Beagle dogs were used for the study. Brain death was induced by the sudden inflation of a subdural balloon catheter with continuous monitoring of arterial blood pressure and eletroencephalographic activity (n=3). Sixteen hours after conformation of brain death, kidney graft were retrieved (n=6). Non-BD donors served as controls (n=4). All kidneys were flushed with University of Wisconsin (UW) solution and preserved for 24 hours at 4$^{\circ}C$ before transplantation. Recipient survival rates, serum creatinine level were analyzed. Brain death induced the well-known Cushing reaction with a severe increase in blood pressure and tachycardia. Thereafter, cardiac function returned progressively to baseline within 8 hours and remained stable until the end of the experiment. All of dogs in both group transplanted were survived until 7 days (100%), and the kidneys showed functional early rejection at 8.3$\pm$0.5 days and 8.5$\pm$0.5 days after transplantation, in BD and allograft group, respectively. BD kidneys were functionally similar to control kidneys for 7 days after transplantated. Brain death has no deleterious effect on preservation injury and survival of dog kidney transplantation, although it induces changes in hemodynamic parameters. This study reveals that kidneys from BD donors do not exhibit more ischemia reperfusion injury, and support good early function and survival.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제33권3호
• /
• pp.241-248
• /
• 2011

Purpose: The aim of this study was to present the clinical results of maxillary sinus augmentation implants and to evaluate the effects of various factors on the implant survival rate. Methods: In a total of 112 patients, 293 implants after sinus augmentation were performed. The total survival rate and the influence of the following factors on implant survival were evaluated; patient characteristics (sex, age, smoking, general disease), graft material, implant surface, implant installation stage, site of implant placement, length and width of implant, closure method for osseous window, residual alveolar bone height. Results: 1. Age ranged from 16 to 70 yr, with a mean of 45.7 yr. 2. Cumulative survival rate for the 293 implants with the maxillary sinus augmentation procedure was 94.9%. 3. Simultaneous implant installation was performed in 122 patients and delayed implant installation was performed in 117 implants. The average healing period after sinus elevation was 7.3 months for delayed implant installation and this procedure had a significantly higher survival rate. 4. There were no significant differences in sex, age, smoking, general disease, site of implant placement, length and width of implant, residual alveolar bone height and the survival rate. 5. RBM (Resorbable Blasting Media) implant surface and allograft groups had significantly lower survival rates. Conclusion: These data suggest that maxillary sinus augmentation may give more predictable results for autogenous bone grafts and delayed implant placement.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제46권3호
• /
• pp.197-203
• /
• 2020

Objectives: We compared the outcomes of two different doses of FK506 (tacrolimus) for immunosuppression in submandibular salivary gland (SMG) allotransplantation. Materials and Methods: Three SMG allotransplantation groups were established (n=6 per group) as follows: allograft rejection control (Allo-Ctrl), low dose (0.08 mg/kg) of FK506 (FK506-L), and high dose (0.16 mg/kg) of FK506 (FK506-H). Allograft survival and rejection were assessed by clinical observation, interleukin-2 levels as determined by enzyme-linked immunosorbent assay, blood sampling for complete blood count (CBC), and histological evaluation. Results: Body weight and anorexia were higher in the FK506-H group but without a significant difference compared with the FK506-L population. CBC revealed a non-significantly reduced number of changes in the FK506-L group. Four glands in the FK506-H group and two glands in the FK506- L group were viable and functioning post-transplantation. Conclusion: The survival rate of allotransplanted glands was higher in conjunction with the high dose of 0.16 mg/kg of FK506, with no major difference in the side-effect profile when compared with the low dose of 0.08 mg/kg short-term outcomes.

• Childhood Kidney Diseases
• /
• 제12권2호
• /
• pp.133-142
• /
• 2008

이식을 위해서는 수여자와 공여자의 혈액형과 HLA type을 알아야 한다. 통상 ABO 혈액형이 적합한 경우 이식할 수 있으며 HLA 부적합은 근래 큰 문제가 되지 않으나 HLA 부적합이 없는 경우 이식장기의 장기생존률이 높다. PRA(panel reactive antibody)는 수여자가 HLA에 감작되었는지 검사하는 방법이며 이식 전에는 반드시 교차반응 검사를 하여 음성인 경우에만 이식을 진행한다. 이식 전후에 donor specific antibody(DSA)를 검사하여 이식장기에 대한 수여자의 면역반응을 예측 할 수 있다. 근래에는 스테로이드, calcineurin inhibitor(cyclosporine, tacrolimus), azathioprine 또는 mycophenolate mofetil (MMF)의 삼제요법을 주로 사용하며 항림프구 항체 (Thymoglobulin 또는 항IL-2 receptor 항체 basiliximab/daclizumab)을 이용하여 이식 초기에 면역억제상태를 induction하는 경우도 많다.

• Journal of Yeungnam Medical Science
• /
• 제41권2호
• /
• pp.134-138
• /
• 2024

Lung retransplantation (LRT) involves a second or subsequent lung transplant (LT) in a patient whose first transplanted graft has failed. LRT is the only treatment option for irreversible lung allograft failure caused by acute graft failure, chronic lung allograft dysfunction, or postoperative complications of bronchial anastomosis. Prehabilitation (rehabilitation before LT), while patients are on the waiting list, is recognized as an essential component of the therapeutic regimen and should be offered throughout the waiting period from the moment of listing until transplantation. LRT is particularly fraught with challenges, and prehabilitation to reduce frailty is one of the few opportunities to address modifiable risk factors (such as functional and motor impairments) in a patient population in which there is clearly room to improve outcomes. Although rehabilitative outcomes and quality of life in patients receiving or awaiting LT have gained increased interest, there is a paucity of data on rehabilitation in patients undergoing LRT. Frailty is one of the few modifiable risk factors of retransplantation that is potentially preventable. As such, it is imperative that professionals involved in the field of retransplantation conduct research specifically exploring rehabilitative techniques and outcomes of value for patients receiving LRT, because this area remains unexplored.